Beijing BIOOCUS Biotech Ltd. is proud to present its innovative product, Atezolizumab, a revolutionary cancer immunotherapy drug. Atezolizumab is a monoclonal antibody that targets the PD-L1 protein, which is commonly expressed on the surface of cancer cells, and works by blocking its interaction with the PD-1 and B7.1 receptors on T cells, thereby enabling the immune system to recognize and attack the cancer cells, This groundbreaking drug has shown remarkable efficacy in the treatment of various types of cancer, including lung cancer, bladder cancer, and triple-negative breast cancer. It has been proven to significantly improve the overall survival rates and progression-free survival in patients with advanced or metastatic cancer, In addition, Atezolizumab has a favorable safety profile, with manageable side effects, making it a preferred choice for cancer patients who are seeking a more tolerable treatment option
Please feel free to give your inquiry in the form below We will reply you in 24 hours